PONTE
VEDRA, Fla., Feb. 8, 2024
/PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD),
a biopharmaceutical company developing tecarfarin, a novel Vitamin
K Antagonist (VKA) for unmet needs in anticoagulation (blood
thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief
Operating Officer. In this role, Mr. Cole will be responsible for
the Company's manufacturing and supply chain operations,
intellectual property, commercialization strategies, and supporting
partnering activities for tecarfarin.
Mr. Cole brings over 25 years of experience in global
pharmaceutical manufacturing and commercial operations, finance,
and corporate development to the Company. This includes senior
executive roles at both private and publicly-traded companies such
as Espero BioPharma, Valeant Pharmaceuticals International (now
Bausch Health Companies), and Legacy Pharmaceuticals. Mr.
Cole co-founded Espero, a biopharmaceutical company focusing on the
late-stage development and commercialization of medicines to treat
cardiovascular diseases, and served as Board Director, President,
and Chief Financial Officer where he was responsible for the
company's supply chain, commercialization, and multiple licensing
and M&A transactions.
"Jeff is an extremely accomplished pharmaceutical operations
executive with a deep understanding of product development,
manufacturing, and commercialization. His experience will serve
Cadrenal well as we advance our tecarfarin clinical program and
evaluate partnering opportunities," commented Quang Pham, Founder, Chairman and Chief
Executive Officer of Cadrenal Therapeutics.
While at Valeant, Mr. Cole held roles of increasing
responsibility, including as General Manager, Vice President of
Corporate Development, and Chief Financial Officer of North America, where revenue more than tripled
during his tenure. As General Manager at Valeant, Mr. Cole managed
a division of U.S. prescription and OTC products across multiple
therapeutic areas with responsibility for product development,
supply, and commercial operations. Prior to the
pharmaceutical industry, Mr. Cole served as Principal in the
Financial Management Consulting practice at
PricewaterhouseCoopers.
"I am excited to be joining the team at Cadrenal at a pivotal
time when demand is increasing for a new anticoagulation therapy to
address the unmet needs for patients with left ventricular assist
devices (LVADs), antiphospholipid syndrome (APS), and those with
end-stage kidney disease (ESKD) and atrial fibrillation (AFib),"
added Jeff Cole. "I look forward to
leveraging my experience to advance tecarfarin to the market and
help those underserved patient groups."
Mr. Cole holds an MBA with honors from the University of Michigan and a BS in accounting from
the University of Southern
California.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs
in anticoagulation therapy. Tecarfarin is a late-stage novel oral
and reversible anticoagulant (blood thinner) to prevent heart
attacks, strokes, and deaths due to blood clots in patients with
certain medical conditions. Tecarfarin has orphan drug and fast
track designations from the FDA for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage kidney disease (ESKD) and atrial fibrillation (AFib).
Cadrenal is also pursuing additional regulatory strategies for
unmet needs in anticoagulation therapy for patients with left
ventricular assist devices (LVADs) and those with thrombotic
antiphospholipid syndrome (APS). Tecarfarin is specifically
designed to leverage a different metabolism pathway than the oldest
and most commonly prescribed Vitamin K Antagonist (warfarin).
Tecarfarin has been evaluated in eleven (11) human clinical trials
and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3
clinical trials, tecarfarin has generally been well-tolerated in
both healthy adult subjects and patients with chronic kidney
disease. For more information, please visit:
www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding the Mr. Cole's experience serving the Company well as it
advances its tecarfarin clinical program and evaluates partnering
opportunities and leveraging Mr. Cole's experience to advance
tecarfarin to the market and help underserved patient
groups. The words "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
expected contribution from Mr. Cole and the ability to
advance tecarfarin with patients with left ventricular assist
devices (LVADs), thrombotic APS, and those with AFib and
ESKD and the other risk factors described in the Company's
Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's subsequent
filings with the SEC, including subsequent periodic reports on
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any
forward-looking statements contained in this press release speak
only as of the date hereof and, except as required by federal
securities laws, the Company specifically disclaims any obligation
to update any forward-looking statement, whether as a result of new
information, future events, or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-appoints-jeff-cole-as-chief-operating-officer-in-advance-of-tecarfarin-phase-3-pivotal-trial-302057004.html
SOURCE Cadrenal Therapeutics, Inc.